Is LXEO or AMLX more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Amylyx Pharmaceuticals N/A -55.69% -50.73%

Which has higher earnings and valuation, LXEO or DMRA?

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.45 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A

Is LXEO or DMRA more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Is LXEO or INBX more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Inhibrx Biosciences N/A -563.90% -72.32%

Lexeo Therapeutics (LXEO) Competitors

$4.24 +0.03 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$4.13 -0.11 (-2.69%)

As of 07:30 PM Eastern

Compare

LXEO vs. AMLX, PGEN, DMRA, INBX, and VIR

Should you buy Lexeo Therapeutics stock or one of its competitors? MarketBeat compares Lexeo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexeo Therapeutics include Amylyx Pharmaceuticals (AMLX), Precigen (PGEN), Damora Therapeutics, Inc. Common Stock (DMRA), Inhibrx Biosciences (INBX), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry.

How does Lexeo Therapeutics compare to Amylyx Pharmaceuticals?

Lexeo Therapeutics (NASDAQ:LXEO) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Lexeo Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Amylyx Pharmaceuticals	$87.37M	17.24	-$144.74M	-$1.50	N/A

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 5.3% of Lexeo Therapeutics shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lexeo Therapeutics' return on equity of -47.48% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Lexeo Therapeutics currently has a consensus price target of $20.14, suggesting a potential upside of 375.07%. Amylyx Pharmaceuticals has a consensus price target of $23.00, suggesting a potential upside of 69.74%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Lexeo Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 5 mentions for Amylyx Pharmaceuticals and 1 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.87 beat Amylyx Pharmaceuticals' score of 0.41 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lexeo Therapeutics	Very Positive
Amylyx Pharmaceuticals	Neutral

Lexeo Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.16, indicating that its share price is 116% less volatile than the broader market.

Summary

Lexeo Therapeutics beats Amylyx Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Precigen?

Lexeo Therapeutics (NASDAQ:LXEO) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Lexeo Therapeutics currently has a consensus target price of $20.14, indicating a potential upside of 375.07%. Precigen has a consensus target price of $12.50, indicating a potential upside of 236.93%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Lexeo Therapeutics is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lexeo Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Precigen	-646.99%	717.50%	58.48%

In the previous week, Precigen had 3 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for Precigen and 1 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.87 beat Precigen's score of 0.98 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lexeo Therapeutics	Very Positive
Precigen	Positive

Lexeo Therapeutics has higher earnings, but lower revenue than Precigen. Precigen is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Precigen	$9.68M	136.64	-$250.64M	-$1.18	N/A

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 5.3% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 47.1% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lexeo Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Precigen has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Summary

Lexeo Therapeutics beats Precigen on 9 of the 15 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Lexeo Therapeutics (NASDAQ:LXEO) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Damora Therapeutics, Inc. Common Stock had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 2 mentions for Damora Therapeutics, Inc. Common Stock and 1 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.87 beat Damora Therapeutics, Inc. Common Stock's score of 1.43 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lexeo Therapeutics	Very Positive
Damora Therapeutics, Inc. Common Stock	Positive

Lexeo Therapeutics' return on equity of -47.48% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Lexeo Therapeutics presently has a consensus target price of $20.14, suggesting a potential upside of 375.07%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $42.00, suggesting a potential upside of 100.38%. Given Lexeo Therapeutics' higher probable upside, equities analysts plainly believe Lexeo Therapeutics is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Lexeo Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 5.3% of Lexeo Therapeutics shares are held by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Lexeo Therapeutics beats Damora Therapeutics, Inc. Common Stock on 8 of the 12 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Inhibrx Biosciences?

Lexeo Therapeutics (NASDAQ:LXEO) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Lexeo Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market.

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 5.3% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lexeo Therapeutics and Lexeo Therapeutics both had 1 articles in the media. Lexeo Therapeutics' average media sentiment score of 1.87 equaled Inhibrx Biosciences'average media sentiment score.

Company	Overall Sentiment
Lexeo Therapeutics	Very Positive
Inhibrx Biosciences	Very Positive

Lexeo Therapeutics' return on equity of -47.48% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Lexeo Therapeutics has higher earnings, but lower revenue than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Inhibrx Biosciences	$1.30M	1,005.46	-$140.05M	-$8.39	N/A

Lexeo Therapeutics currently has a consensus target price of $20.14, indicating a potential upside of 375.07%. Inhibrx Biosciences has a consensus target price of $150.00, indicating a potential upside of 68.35%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lexeo Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Lexeo Therapeutics beats Inhibrx Biosciences on 7 of the 11 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Vir Biotechnology had 8 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 9 mentions for Vir Biotechnology and 1 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.87 beat Vir Biotechnology's score of 0.48 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Vir Biotechnology	Neutral
Lexeo Therapeutics	Very Positive

Lexeo Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Lexeo Therapeutics' return on equity of -47.48% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Vir Biotechnology has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

Lexeo Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	20.93	-$437.99M	-$3.13	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

Vir Biotechnology currently has a consensus target price of $20.38, suggesting a potential upside of 139.42%. Lexeo Therapeutics has a consensus target price of $20.14, suggesting a potential upside of 375.07%. Given Lexeo Therapeutics' higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Lexeo Therapeutics beats Vir Biotechnology on 8 of the 14 factors compared between the two stocks.

Get Lexeo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXEO vs. The Competition

Export

Metric	Lexeo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$330.58M	$2.95B	$6.68B	$11.95B
Dividend Yield	N/A	1.70%	2.67%	5.58%
P/E Ratio	N/A	17.78	24.56	23.76
Price / Sales	N/A	705.38	566.69	129.97
Price / Cash	N/A	56.17	26.99	37.23
Price / Book	1.25	3.88	10.52	6.75
Net Income	-$99.96M	$75.85M	$3.56B	$337.35M
7 Day Performance	-5.99%	-1.46%	-1.11%	-2.54%
1 Month Performance	-27.27%	-5.33%	1.28%	1.42%
1 Year Performance	-3.20%	15.77%	21.20%	24.71%

Lexeo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXEO Lexeo Therapeutics	2.3442 of 5 stars	$4.24 +0.7%	$20.14 +375.1%	+8.5%	$330.58M	N/A	N/A	58	Positive News Gap Up
AMLX Amylyx Pharmaceuticals	2.5934 of 5 stars	$13.46 -6.2%	$23.00 +70.9%	+144.1%	$1.60B	$87.37M	N/A	200	News Coverage Analyst Forecast
PGEN Precigen	3.2344 of 5 stars	$3.93 -9.6%	$12.50 +218.5%	+138.0%	$1.55B	$9.68M	N/A	190
DMRA Damora Therapeutics, Inc. Common Stock	2.4459 of 5 stars	$24.85 -0.1%	$42.00 +69.0%	+535.6%	$1.53B	N/A	N/A	40	Positive News Analyst Forecast
INBX Inhibrx Biosciences	2.6935 of 5 stars	$93.26 -10.3%	$150.00 +60.8%	+540.3%	$1.53B	$1.30M	N/A	166	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXEO) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. AMLX, PGEN, DMRA, INBX, and VIR

How does Lexeo Therapeutics compare to Amylyx Pharmaceuticals?

Summary

How does Lexeo Therapeutics compare to Precigen?

Summary

How does Lexeo Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Lexeo Therapeutics compare to Inhibrx Biosciences?

Summary

How does Lexeo Therapeutics compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. AMLX, PGEN, DMRA, INBX, and VIR

How does Lexeo Therapeutics compare to Amylyx Pharmaceuticals?

Which has preferable valuation & earnings, LXEO or AMLX?

Do institutionals & insiders hold more shares of LXEO or AMLX?

Is LXEO or AMLX more profitable?

Do analysts rate LXEO or AMLX?

Does the media prefer LXEO or AMLX?

Which has more risk and volatility, LXEO or AMLX?

Summary

How does Lexeo Therapeutics compare to Precigen?

Do analysts prefer LXEO or PGEN?

Is LXEO or PGEN more profitable?

Does the media prefer LXEO or PGEN?

Which has stronger earnings and valuation, LXEO or PGEN?

Do institutionals and insiders believe in LXEO or PGEN?

Which has more risk and volatility, LXEO or PGEN?

Summary

How does Lexeo Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Does the media prefer LXEO or DMRA?

Is LXEO or DMRA more profitable?

Which has higher earnings and valuation, LXEO or DMRA?

Do analysts prefer LXEO or DMRA?

Which has more risk & volatility, LXEO or DMRA?

Do institutionals & insiders have more ownership in LXEO or DMRA?

Summary

How does Lexeo Therapeutics compare to Inhibrx Biosciences?

Which has more risk & volatility, LXEO or INBX?

Do institutionals & insiders believe in LXEO or INBX?

Does the media favor LXEO or INBX?

Is LXEO or INBX more profitable?

Which has better valuation and earnings, LXEO or INBX?

Do analysts rate LXEO or INBX?

Summary

How does Lexeo Therapeutics compare to Vir Biotechnology?

Do institutionals and insiders hold more shares of VIR or LXEO?

Does the media prefer VIR or LXEO?

Is VIR or LXEO more profitable?

Which has more volatility & risk, VIR or LXEO?

Which has stronger valuation and earnings, VIR or LXEO?

Do analysts rate VIR or LXEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools